This post first appeared on SEC Filings – Market Exclusive

RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) Files An 8-K Other Events
Item 8.01. Other Events

As previously disclosed in a Form 10-Q for the quarterly period ended on March 31, 2019 filed with the Securities and Exchange Commission on May 15, 2019, and in a current report on Form 8-K filed on June 20, 2019, Relmada Therapeutics, Inc. (the “Company”) entered into Securities Purchase Agreements with various accredited investors to which the Company sold common stock and warrants for gross proceeds of approximately $11.4 million. Subsequently, on June 28, 2019 the Company sold an additional 286,756 shares of common stock and 143,377 warrants for gross proceeds of approximately $0.4 million.

Attached hereto as Exhibit 99.1 is a proforma balance sheet as of March 31, 2019 giving effect to the closings and receipt by the Company of the net proceeds of the offerings.

Item 9.01. Financial Statements and Exhibits.

99.1 Proforma balance sheet as of March 31, 2019.


RELMADA THERAPEUTICS, INC. Exhibit
EX-99.1 2 f8k071719a1ex99-1_relmada.htm PROFORMA BALANCE SHEET AS OF MARCH 31,…
To view the full exhibit click here

About RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD)

Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to treat chronic pain. Its product candidates include d-Methadone (dextromethadone, REL-1017), LevoCap ER (REL-1015), BuTab (REL-1028) and MepiGel (REL-1021). Its d-Methadone is an N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. Its REL-1015 is an extended release, abuse deterrent formulation of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other opioids for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. REL-1028 represents formulations of oral, modified release buprenorphine being developed for both chronic pain and opioid dependence indications. REL-1021 is a topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies.

The post RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) Files An 8-K Other Events appeared first on Market Exclusive.

--
Copyright in text and images in this article belong to the original source.

This post first appeared on SEC Filings – Market Exclusive